

TRUSTEES REPORT (INCLUDING DIRECTORS REPORT)

YEAR ENDED 31 AUGUST 2021

The trustees, who are also directors of the charity for the purposes of the Companies Act 2006, present their report and unaudited financial statements of the charity for the year ending 31 August 2021.

Trustees

The trustees, who are also the directors for the purposes of company law, and who served during the year and up to the date of signature of the unaudited financial statements were:

Prof J Newell-Price

Prof J Ramage

Prof T H Shah

Prof C Thirlwell – appointed 2 December 2019

None of the directors has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of winding up.

The Society has two main categories of membership as follows: Clinician and Consultant Members; Trainee, Nurse, Scientist and Allied Health Professional Members. The latter are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or organisations interested in promoting the objects.

Governing document

The UK and Ireland Neuroendocrine Tumour Society Limited (UKI NETS) is constituted by its Memorandum & Articles of Association, adopted by the membership on 1 December 2014, and is a registered charity. UKI NETS became a company limited by guarantee on 13 August 2008 and was subsequently registered as a charity on 16 July 2012.

Organisational structure

The Society has two main categories of membership as follows: Clinician and Consultant Members; Trainee, Nurse, Scientist and Allied Health Professional Members. The latter are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or organisations interested in promoting the objects.

The Society is governed by four Executive Officers, who are the directors and trustees (Chair, Past Chair, Treasurer and Secretary), supported by a wider Executive Committee, which includes chairs of the sub committees.

Risk management

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.

TRUSTEES REPORT (INCLUDING DIRECTORS REPORT)

YEAR ENDED 31 AUGUST 2021

Objectives and activities

The charity's objects are to promote for the public benefit research, education and clinical practice in neuroendocrine tumours by the organisation of conferences, training courses and publications, by raising public awareness, liaison with national and international legislators, and by any other appropriate means. The Society aims to improve the diagnosis and therapy of patients with neuroendocrine tumours within a national multidisciplinary and scientific context.

In furtherance of its objects, the Society shall have the following powers:

1. To arrange and provide for the holding of meetings, lectures and seminars.
2. To procure to be written and print, publish, issue and circulate gratuitously or otherwise such papers, periodicals, pamphlets or other documents.
3. To raise funds and to invite and receive contributions from any person or persons whatsoever by way of subscriptions and otherwise provided that the Society shall not undertake any permanent trading activities in raising funds for its primary charitable objectives.
4. To co-operate, associate or affiliate with any other charitable institutions.
5. To do all such other lawful things as are necessary for the attainment of the above objectives.

The summary of main activities in relation to the charity objectives are as follows:

- Annual Scientific Meeting
- Provision of travel grants
- Provision of meeting awards
- Allocation of research grants
- Provision of educational activities
- Guideline development
- Public engagement

Achievements and performance

UKI NETS 18th Annual Conference: Online 2020

The 18th Annual Conference of the Society was held Online on Monday 30 November 2020. This was the first time that the conference had been held virtually, due to the COVID-19 pandemic. The Society welcomed 208 people to the event, only 21 fewer than the previous years' event which was held in London in 2019.

Sessions ran from early afternoon until early evening, focusing on NET Diagnostic Approaches over the last 20 years from Surgical, Gastroenterology, Endocrinology, Medical Oncology approach and the Patient Perspective. 'Challenging the Experts' sessions reviewed three selected trainee case presentations, focusing on everyday NET challenges and inviting questions and discussion. Oral abstract presentations held on day

4 included topics such as Liver metastases of neuroendocrine neoplasms, Omic Gene Clusters and the challenges presented by COVID-19 to the NCUK care experience. The conference ended with a Prize Giving session.

TRUSTEES REPORT (INCLUDING DIRECTORS REPORT)

YEAR ENDED 31 AUGUST 2021

Provision of travel grants

As the conference was held online in 2020, no travel grants were awarded.

Provision of meeting awards

Prizes were awarded to the best scoring clinical and scientific posters and oral communication at the 18th Annual Conference.

Provision of Research grants

UKI NETS and the NET Patient Foundation awarded one research grant of £25k to provide pump-priming funds to support research a project aimed at improving outcomes for patients with Neuroendocrine Tumours.

Public Engagement

UKI NETS members speak regularly at regional events aimed to help NET patients across the UK in collaboration with the NET Patient Foundation and other organisations.

Educational activities

UKINETS organised a NETs for Newcomers Training Day (formerly NET Basics Day) that was postponed until May 2021 and held online, due to the COVID-19 pandemic. The aims of this training day were to give participants (including doctors of all specialties) in the management of Neuroendocrine Tumours and:

1. To feel confident to plan outpatient care and initial investigations for a patient with a NET
2. To be able to present the patient to the NET MDT including awareness of terminology
3. To independently manage side effects of carcinoid syndrome and commonly used treatments for NET tumours

UKINETS continues to expand its Library of Bitesize Guidance which is available on the UKINETS website. These are accessible clinical documents relating to specific areas of NET management.

Sessions included a Q&A with a panel of International experts and encouraged lots of interaction.

Dietitians' Working Group

The chair of the dietitians' working group remained as a co-optee on the Executive Committee.

Sponsor Support

There was financial support to the Society in the form of sponsorship from companies throughout the pharmaceutical industry. The majority of the funding was provided as sponsorship for the National Conference and NETs Basics Training Day. Sponsorship packages were developed by the Treasurer to give companies options for different levels and areas of support moving forwards.

TRUSTEES REPORT (INCLUDING DIRECTORS REPORT)

YEAR ENDED 31 AUGUST 2021

Website

The charity's website provides an important tool to inform members and the general public about the activities of the Society. <http://www.ukinets.org>.

Communications

UKI NETS communicates with its members by means of a newsletter containing highlights from previous conferences, information on clinical trials and other Society news. In addition, the charity highlights on its website news stories from the media relating to the field of neuroendocrine tumours. The charity also has its own Twitter account @UKINETs.

PROMNET app

Along with the NET Patient Foundation, UKINETs continued to be involved in a project to develop a mobile application to empower patients with regards to managing their neuroendocrine tumour. The app gained IRAS approval in 2020 and will act as a tool for patients to track their symptoms, collect data and communicate with the clinical team. The development of the app was funded by Imaging Equipment Ltd.

Clinical Trials

The NET Clinical Studies Group which monitors and compiles summaries of clinical trials presents updates and reports at the UKINETs Annual Conference. The Research SubCommittee of UKINETs also aims to keep the UKINETs website and NET Patient Foundation up to date with trials that are currently recruiting.

COVID-19

UKINETs released guidance and statements regarding the evolving COVID-19 pandemic and its impact on NET patients and their HCPs.

Link with the European Neuroendocrine Tumour Society (ENETS)

UKI NETS continues to provide free membership to its members to its European partner Society, ENETS. Through membership of ENETS, UKI NETS members have access to the

journal *Neuroendocrinology* and a reduced rate for the ENETS annual conference. This inclusive membership is optional for trainees, nurses, scientists and allied health professionals.

Financial review

Principal funding sources

Income to the Society is mainly generated through industry support, the annual conference and membership subscriptions. Personal donations/legacies are received on an ad hoc basis.

Reserves policy

The reserve policy takes into consideration the major risks that could face the Society.

It is the policy of the Society to maintain unrestricted funds, which are the free reserves of the charity. The reserves are held at a level that ensures the financial viability of the Society. That level is deemed to be one that equates to a minimum of one year's expenditure. The balance sheet indicates that there are £124,035 unrestricted funds as at 31 August 2021. This provides sufficient funds to cover management, administration and support costs.

TRUSTEES REPORT (INCLUDING DIRECTORS REPORT

YEAR ENDED 31 AUGUST 2021

Plans for future periods

The UKI NETS 19th Annual Conference is scheduled to be held virtually in December 2021 due to the coronavirus pandemic. The first day will celebrate the history of UKI NETS and Advances in NET Diagnostic Approach.

Abstracts have been submitted as usual and prizes will be awarded to the highest scoring presentations during the conference.

Other plans for the coming year include:

- Holding a further NETs for Newcomers training event virtually in February 2021 due to its postponement in 2020 – held in May 2021.
- Further developing the library of bite size clinical guidance for the website and reviewing older guidelines
- Developing a Carcinoid Heart Disease Conference postponed from 2020
- Delivery of broader training for nurses, AHPs, GPs, junior doctors and other non-specialists
- Development of a liver transplantation delivery programme and associated service development and research opportunities, in collaboration with LAG, NHFBT and SIGTO.
- Development of additional online content for UKI NETS members
- UKI NETS coordination of European NET studies in the UK
- NET dietetics survey and guidance
- Annual conference plans to be confirmed in accordance with COVID-19
- Providing feedback on external clinical guidelines
- Continuing to secure funding from corporate donors
- Continuing to develop communications with members

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

Working with other societies and foundations to fund and promote NETS knowledge and research

The Trustees Report was approved by the Board of Trustees and signed on its behalf by:

Prof T H Shah

Trustee

Dated:

Charity Registration Number: 1148145

Company Registration Number: 06672185 (England and Wales)

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2021

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

CONTENTS

	Page
Legal and administrative information	2
Trustees' Report	3 to 7
Independent examiners report	8
Statement of financial activities	9
Balance sheet	10
Notes to the financial statements	11 to 17

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees

Prof J Newell-Price
Prof J Ramage
Prof T H Shah
Prof C Thirwell

Registered Office

138 Digbeth
Birmingham
B5 6DR

Charity number: 1148145

Company number: 06672185 (registered in England and Wales)

Independent Examiner

Paul Bowater
BVSC Accountancy Services
First Floor
Livery Place
35 Livery Street
Birmingham
B3 2PB

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2021

The trustees, who are also directors of the charity for the purposes of the Companies Act 2006, present their report and unaudited financial statements of the charity for the year ending 31 August 2021.

Trustees

The trustees, who are also the directors for the purposes of company law, and who served during the year and up to the date of signature of the unaudited financial statements were:

Prof J Newell-Price

Prof J Ramage

Prof T H Shah

Prof C Thirlwell

None of the directors has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of winding up.

The Society has two main categories of membership as follows: Clinician and Consultant Members; Trainee, Nurse, Scientist and Allied Health Professional Members. The latter are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or organisations interested in promoting the objects.

Governing document

The UK and Ireland Neuroendocrine Tumour Society Limited (UKI NETS) is constituted by its Memorandum & Articles of Association, adopted by the membership on 1 December 2014, and is a registered charity. UKI NETS became a company limited by guarantee on 13 August 2008 and was subsequently registered as a charity on 16 July 2012.

Organisational structure

The Society has two main categories of membership as follows: Clinician and Consultant Members; Trainee, Nurse, Scientist and Allied Health Professional Members. The latter are given the option of membership with or without inclusive ENETS membership. Membership of the charity is open to any medical professionals or organisations interested in promoting the objects.

The Society is governed by four Executive Officers, who are the directors and trustees (Chair, Past Chair, Treasurer and Secretary), supported by a wider Executive Committee, which includes chairs of the sub committees.

Risk management

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2021

Objectives and activities

The charity's objects are to promote for the public benefit research, education and clinical practice in neuroendocrine tumours by the organisation of conferences, training courses and publications, by raising public awareness, liaison with national and international legislators, and by any other appropriate means. The Society aims to improve the diagnosis and therapy of patients with neuroendocrine tumours within a national multidisciplinary and scientific context.

In furtherance of its objects, the Society shall have the following powers:

1. To arrange and provide for the holding of meetings, lectures and seminars.
2. To procure to be written and print, publish, issue and circulate gratuitously or otherwise such papers, periodicals, pamphlets or other documents.
3. To raise funds and to invite and receive contributions from any person or persons whatsoever by way of subscriptions and otherwise provided that the Society shall not undertake any permanent trading activities in raising funds for its primary charitable objectives.
4. To co-operate, associate or affiliate with any other charitable institutions.
5. To do all such other lawful things as are necessary for the attainment of the above objectives.

The summary of main activities in relation to the charity objectives are as follows:

- Annual Scientific Meeting
- Provision of travel grants
- Provision of meeting awards
- Allocation of research grants
- Provision of educational activities
- Guideline development
- Public engagement

Achievements and performance

UKI NETS 18th Annual Conference: Online 2020

The 18th Annual Conference of the Society was held Online on Monday 30 November 2020. This was the first time that the conference had been held virtually, due to the COVID-19 pandemic. The Society welcomed 208 people to the event, only 21 fewer than the previous years' event which was held in London in 2019.

Sessions ran from early afternoon until early evening, focusing on NET Diagnostic Approaches over the last 20 years from Surgical, Gastroenterology, Endocrinology, Medical Oncology approach and the Patient Perspective. 'Challenging the Experts' sessions reviewed three selected trainee case presentations, focusing on everyday NET challenges and inviting questions and discussion. Oral abstract presentations held on day 4 included topics such as Liver metastases of neuroendocrine neoplasms, Omic Gene Clusters and the challenges presented by COVID-19 to the NCUK care experience. The conference ended with a Prize Giving session.

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2021

Provision of travel grants

As the conference was held online in 2020, no travel grants were awarded.

Provision of meeting awards

Prizes were awarded to the best scoring clinical and scientific posters and oral communication at the 18th Annual Conference.

Provision of Research grants

UKI NETS and the NET Patient Foundation awarded one research grant of £25k to provide pump-priming funds to support research a project aimed at improving outcomes for patients with Neuroendocrine Tumours.

Public Engagement

UKI NETS members speak regularly at regional events aimed to help NET patients across the UK in collaboration with the NET Patient Foundation and other organisations.

Educational activities

UKINETS organised a NETs for Newcomers Training Day (formerly NET Basics Day) that was postponed until May 2021 and held online, due to the COVID-19 pandemic. The aims of this training day were to give participants (including doctors of all specialties) in the management of Neuroendocrine Tumours and:

1. To feel confident to plan outpatient care and initial investigations for a patient with a NET
2. To be able to present the patient to the NET MDT including awareness of terminology
3. To independently manage side effects of carcinoid syndrome and commonly used treatments for NET tumours

UKINETS continues to expand its Library of Bitesize Guidance which is available on the UKINETS website. These are accessible clinical documents relating to specific areas of NET management.

Sessions included a Q&A with a panel of International experts and encouraged lots of interaction.

Dietitians' Working Group

The chair of the dietitians' working group remained as a co-optee on the Executive Committee.

Sponsor Support

There was financial support to the Society in the form of sponsorship from companies throughout the pharmaceutical industry. The majority of the funding was provided as sponsorship for the National Conference and NETs Basics Training Day. Sponsorship packages were developed by the Treasurer to give companies options for different levels and areas of support moving forwards.

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

TRUSTEES REPORT (INCLUDING DIRECTORS REPORT) YEAR ENDED 31 AUGUST 2021

Website

The charity's website provides an important tool to inform members and the general public about the activities of the Society. <http://www.ukinets.org>.

Communications

UKI NETS communicates with its members by means of a newsletter containing highlights from previous conferences, information on clinical trials and other Society news. In addition, the charity highlights on its website news stories from the media relating to the field of neuroendocrine tumours. The charity also has its own Twitter account @UKINETs.

PROMNET app

Along with the NET Patient Foundation, UKINETs continued to be involved in a project to develop a mobile application to empower patients with regards to managing their neuroendocrine tumour. The app gained IRAS approval in 2020 and will act as a tool for patients to track their symptoms, collect data and communicate with the clinical team. The development of the app was funded by Imaging Equipment Ltd.

Clinical Trials

The NET Clinical Studies Group which monitors and compiles summaries of clinical trials presents updates and reports at the UKINETs Annual Conference. The Research SubCommittee of UKINETs also aims to keep the UKINETs website and NET Patient Foundation up to date with trials that are currently recruiting.

COVID-19

UKINETs released guidance and statements regarding the evolving COVID-19 pandemic and its impact on NET patients and their HCPs.

Link with the European Neuroendocrine Tumour Society (ENETS)

UKI NETS continues to provide free membership to its members to its European partner Society, ENETS. Through membership of ENETS, UKI NETS members have access to the journal *Neuroendocrinology* and a reduced rate for the ENETS annual conference. This inclusive membership is optional for trainees, nurses, scientists and allied health professionals.

Financial review

Principal funding sources

Income to the Society is mainly generated through industry support, the annual conference and membership subscriptions. Personal donations/legacies are received on an ad hoc basis.

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

TRUSTEES REPORT (INCLUDING DIRECTORS REPORT YEAR ENDED 31 AUGUST 2021

Reserves policy

The reserve policy takes into consideration the major risks that could face the Society.

It is the policy of the Society to maintain unrestricted funds, which are the free reserves of the charity. The reserves are held at a level that ensures the financial viability of the Society. That level is deemed to be one that equates to a minimum of one year's expenditure. The balance sheet indicates that there are £124,035 unrestricted funds as at 31 August 2021. This provides sufficient funds to cover management, administration and support costs.

Plans for future periods

The UKI NETS 19th Annual Conference is scheduled to be held virtually in December 2021 due to the coronavirus pandemic. The first day will celebrate the history of UKI NETS and Advances in NET Diagnostic Approach.

Abstracts have been submitted as usual and prizes will be awarded to the highest scoring presentations during the conference.

Other plans for the coming year include:

- Holding a further NETs for Newcomers training event virtually in February 2021 due to its postponement in 2020 – held in May 2021.
- Further developing the library of bite size clinical guidance for the website and reviewing older guidelines
- Developing a Carcinoid Heart Disease Conference postponed from 2020
- Delivery of broader training for nurses, AHPs, GPs, junior doctors and other non-specialists
- Development of a liver transplantation delivery programme and associated service development and research opportunities, in collaboration with LAG, NHFBT and SIGTO.
- Development of additional online content for UKI NETS members
- UKI NETs coordination of European NET studies in the UK
- NET dietetics survey and guidance
- Annual conference plans to be confirmed in accordance with COVID-19
- Providing feedback on external clinical guidelines
- Continuing to secure funding from corporate donors
- Continuing to develop communications with members


Working with other societies and foundations to fund and promote NETS knowledge and research

The Trustees Report was approved by the Board of Trustees and signed on its behalf by:

Prof T H Shah

Trustee

Dated:


11/07/2022

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

INDEPENDENT EXAMINERS REPORT TO THE TRUSTEES OF UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

I report to the trustees on my examination of the financial statements of UK and Ireland Neuroendocrine Tumour Society Limited for the year ending 31 August 2021.

Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for an independent examination. I report in respect of the examination of the charity's financial statements carried out under section 144 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
2. the financial statements do not accord with those records; or
3. the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).;

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Paul Bowater ACA
BVSC Accountancy Services
First Floor
Livery Place
35 Livery Street
Birmingham
B3 2PB

Dated: 11/07/22

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT)

YEAR ENDED 31 AUGUST 2021

	Note	Unrestricted funds	Restricted funds	Total	Total
		2021	2021	2021	2020
		£	£	£	£
<u>Income from:</u>					
Donations and legacies	3	17,121	-	17,121	16,544
<u>Charitable activities</u>					
Sponsorship	4	78,045	-	78,045	117,983
Grants	4	-	-	-	-
Total income		95,166	95,166	95,166	134,527
<u>Expenditure on:</u>					
<u>Charitable activities</u>					
Research grant		-	-	-	-
Other charitable expenditure	5	74,905	10,800	85,705	97,691
Total charitable expenditure		74,905	10,800	85,705	97,691
Other resources expended		95	-	95	68
Total resources expended		75,000	10,800	85,800	97,759
Net income for the year/Net movement in funds		20,166	(10,800)	9,366	36,768
Fund balances at 1 September 2020		103,869	34,325	138,194	101,426
Fund balances at 31 August 2021		124,035	23,525	147,560	138,194

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

BALANCE SHEET AS AT 31 AUGUST 2021

	Note	2021 £	2020 £
Fixed assets	9	-	-
Current assets			
Debtors	11	64,327	13,599
Cash at bank and in hand		98,765	136,439
		<u>163,092</u>	<u>150,038</u>
Creditors: amounts falling due with one year	12	(15,532)	(11,844)
Net current assets		<u>147,560</u>	<u>138,194</u>
Total assets less current liabilities		<u>147,560</u>	<u>138,194</u>
Income funds			
Restricted funds	14	23,525	34,325
Unrestricted funds		124,035	103,869
		<u>147,560</u>	<u>138,194</u>

For the year ending 31 August 2021 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. No members have required the company to obtain an audit of the financial statements for the year ending 31 August 2021 in accordance with section 476 of the Companies Act 2006.


The trustees acknowledge their responsibilities for ensuring that the charity keeps accounting records which comply with section 386 of the Act and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its incoming resources and application of resources, including its income and expenditure, for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees on , and signed on behalf of the board by:

Prof T H Shah

Trustee


11/07/2022

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2021

1. Accounting Policies

Accounting convention

The accounts have been prepared in accordance with the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice (SORP) applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The charity is a "Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Incoming resources

These are included in the Statement of Financial Activities (SOFA) when:

- The charity becomes legally entitled to the resources after any performance conditions have been met;
- The trustees are virtually certain that they will receive the resources; and
- The monetary value can be measured with sufficient reliability.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount.

Charitable income includes sponsorship of the annual conference and contributions towards the charity's objectives.

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2021

1. Accounting Policies (continued)

Resources expended

Charitable activities includes all costs relating to the conference, newsletters and general administration, which support the charitable purpose.

Grants offered subject to conditions, which have not been met at the year-end date are noted as a commitment, but not accrued as expenditure.

Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Where costs cannot be directly attributed to particular headings that have been allocated to activities on a basis consistent with the use of the resources.

Incoming resources with related expenditure

When incoming resources have related expenditure (as with fundraising or contract income) both are reported gross in the SOFA.

Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values their useful lives on the following bases:

Computers – straight line over 3 years

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with bankers, other short term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Financial instruments

The charity has elected to apply the provisions of Section 11 "Basic Financial Instruments" and Section 12 "Other Financial Issues" of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2020

1. Accounting Policies (continued)

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the assets and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price, including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market value of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

De-recognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

2. Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3. Donations and legacies

	Unrestricted Funds	Restricted funds	Total	Total
	2021 £	2021 £	2021 £	2020 £
Donations and gifts	-	-	-	2,188
Membership fees	17,121	-	17,121	14,359
Total for the year	<u>17,121</u>	<u>-</u>	<u>17,121</u>	<u>16,544</u>

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2021

4. Charitable activities

	Sponsorship	Grants	Total	Total
	2021 £	2021 £	2021 £	2020 £
Sales within charitable activities	78,045	-	78,045	117,983
Performance related grants	-	-	-	-
Total for the year	<u>78,045</u>	<u>-</u>	<u>78,045</u>	<u>117,983</u>

Analysis by fund

Unrestricted funds				117,983
Restricted funds	-	-	-	-
	<u>-</u>	<u>-</u>	<u>-</u>	<u>117,983</u>

5. Charitable activities

	2021 £	2020 £
Depreciation and impairment	-	-
Conferences and newsletters	20,484	42,720
	<u>20,484</u>	<u>42,720</u>
Share of support costs (note 6)	29,818	27,602
Share of governance costs (note 6)	24,603	20,169
Application developments costs	10,800	7,200
	<u>85,705</u>	<u>97,691</u>

Analysis by fund

Unrestricted funds	74,905	87,638
Restricted funds	10,800	10,053
	<u>85,705</u>	<u>97,691</u>

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2021

6. Support costs

	Support costs	Governance costs	Total	Total
	2021 £	2021 £	2021 £	2020 £
ENET membership subscriptions	12,178	-	12,178	7,723
Website	3,090	-	3,090	3,679
Management fees	14,550	-	14,550	16,200
Independent examiner and accountancy fees	-	1,440	1,440	1,440
Other operating costs	-	18,620	18,620	18,260
Committee meetings	-	4,543	4,543	469
	<u>29,818</u>	<u>24,603</u>	<u>54,421</u>	<u>47,771</u>
Analysed between Charitable activities	<u>29,818</u>	<u>24,603</u>	<u>54,421</u>	<u>47,771</u>

7. Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year (2020 - £nil).

8. Employees

There were no employees during the year. (2020 - nil).

9. Tangible fixed assets

	Computers £
Cost	
At 1 September 2020 and 31 August 2021	<u>10,420</u>
Depreciation and impairment	
At 1 September 2020 and 31 August 2021	<u>10,420</u>
Carrying amount	
At 31 August 2021	<u>-</u>
At 31 August 2020	<u>-</u>
Charitable activities	

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2021

10. Financial instruments

	2021 £	2020 £
Carrying amount of financial assets		
Debt instruments measured at amortised cost	-	-
Carrying value of financial liabilities		
Measured on amortised costs	-	-

11. Debtors

	2021 £	2020 £
Amounts falling due within one year		
Other debtors	10,000	10,000
Prepayments and accrued income	54,327	3,599
	<u>64,327</u>	<u>13,599</u>

12. Creditors: amounts falling due within one year

	2021 £	2020 £
Deferred income	4,732	2,312
Accruals	10,800	9,532
	<u>15,532</u>	<u>11,844</u>

13. Other deferred income

	2021 £	2020 £
Other deferred income	<u>4,732</u>	<u>2,312</u>

UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 AUGUST 2021

14. Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Balance at 1 September 2020	Movement in funds		Balance at 31 August 2021
	£	Incoming resources	Resources expended	£
		£	£	
Grants	11,150	-	-	11,150
TransNET	4,925	-	-	4,925
Mobile app development	18,250	-	10,800	7,450
	<u>34,325</u>	<u>-</u>	<u>10,800</u>	<u>23,525</u>

15. Analysis of net assets between funds

Fund balances at 31 August 2021 and 31 August 2020 are represented by current assets/(liabilities).

16. Related party transaction

There were no disclosable related party transactions during the year (2020 – none).

INDEPENDENT EXAMINERS REPORT TO THE TRUSTEES OF UK AND IRELAND NEUROENDOCRINE TUMOUR SOCIETY LIMITED

I report to the trustees on my examination of the financial statements of UK and Ireland Neuroendocrine Tumour Society Limited for the year ending 31 August 2021.

Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).


Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for an independent examination. I report in respect of the examination of the charity's financial statements carried out under section 144 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
2. the financial statements do not accord with those records; or
3. the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).;

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Paul Bowater ACA
BVSC Accountancy Services
First Floor
Livery Place
35 Livery Street
Birmingham
B3 2PB

Dated: 11 July 2022